Ann Hematol (2017) 96:1569–1572 DOI 10.1007/s00277-017-3033-7 LETTER TO THE EDITOR Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic haematopoietic stem cell transplantation 1 1 1 Thomas S. Y. Chan & Joycelyn P. Y. Sim & Yok-Lam Kwong Received: 22 May 2017 /Accepted: 23 May 2017 /Published online: 1 June 2017 Springer-Verlag Berlin Heidelberg 2017 Dear Editor, Patient 1 was a 31-year-old woman presenting in 2013 with Relapse of acute leukaemia after allogeneic haematopoietic B cell ALL. Induction chemotherapy with hyper-CVAD (cy- stem cell transplantation (HSCT) has a dismal prognosis, de- clophosphamide, vincristine, doxorubicin, steroid, cytarabine, spite the use of chemotherapy, donor lymphocyte infusion methotrexate) resulted in first complete remission (CR1). She underwent a matched unrelated donor (MUD)-HSCT. Relapse (DLI) or second HSCT . For relapses within 1 year post- HSCT, current strategies lead to survival in fewer than 10% of occurred 10 months later, and CR2 was achieved with MOAD cases [1, 2]. (methotrexate, vincristine, L-asparaginase, dexamethasone). Immunotherapy including the use of monoclonal antibod- She then received a second MUD-HSCT from a different do- ies inotuzumab ozogamicin (anti-CD22) and blinatumomab nor. Five months later, multiple subcutaneous nodules, renal (anti-CD19) , and chimeric antigen receptor T cells ,
Annals of Hematology – Springer Journals
Published: Jun 1, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera